To address this dilemma, efforts are being made to diagnose SMA as early as possible, and many countries have now adopted prenatal and/or newborn screening to identify common pathogenic SMN1 mutations and patients to be treated. This evidence concerns the gene SMN1 and proximal spinal muscular atrophy.